GeoVax Labs Inc Total Liabilities
GeoVax Labs Inc total liabilities. Based on the latest financial reports, GeoVax Labs Inc (GOVX) has total liabilities worth $1.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See GOVX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of GeoVax Labs Inc (1996–2024)
Total liabilities of GeoVax Labs Inc from 1996 to 2024. This chart illustrates how GeoVax Labs Inc's total liabilities have evolved over time, based on quarterly financial data.
GeoVax Labs Inc Competitors by Total Liabilities
The table below lists competitors of GeoVax Labs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SysGroup PLC
LSE:SYS
|
UK | GBX14.56 Million |
|
Nevada Zinc Corp
V:NZN
|
Canada | CA$630.72K |
|
Sparx Technology Inc
V:SPRX
|
Canada | CA$1.32 Million |
|
Palace Capital PLC
LSE:PCA
|
UK | GBX2.36 Million |
|
Wheeler Real Estate Investment Trust, Inc.
NASDAQ:WHLR
|
USA | $502.61 Million |
|
Israel Opportunity - Energy Resources LP
TA:ISOP-L
|
Israel | ILA259.00K |
|
Wildpack Beverage Inc
V:CANS
|
Canada | CA$141.24 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down GeoVax Labs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see GOVX total asset value.
Liquidity & Leverage Metrics
GeoVax Labs Inc Total Liabilities Ratios Explained
GeoVax Labs Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeoVax Labs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeoVax Labs Inc (1996–2024)
The table below shows the annual total liabilities of GeoVax Labs Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.11 Million | -11.72% |
| 2023-12-31 | $3.52 Million | -25.87% |
| 2022-12-31 | $4.75 Million | -36.14% |
| 2021-12-31 | $7.43 Million | +801.21% |
| 2020-12-31 | $825.00K | -59.63% |
| 2019-12-31 | $2.04 Million | +22.80% |
| 2018-12-31 | $1.66 Million | +105.10% |
| 2017-12-31 | $811.29K | +119.36% |
| 2016-12-31 | $369.85K | +191.24% |
| 2015-12-31 | $126.99K | -32.10% |
| 2014-12-31 | $187.02K | -40.12% |
| 2013-12-31 | $312.35K | -4.49% |
| 2012-12-31 | $327.04K | -65.27% |
| 2011-12-31 | $941.53K | +80.51% |
| 2010-12-31 | $521.61K | -8.71% |
| 2009-12-31 | $571.37K | +64.93% |
| 2008-12-31 | $346.42K | -42.12% |
| 2007-12-31 | $598.54K | +209.94% |
| 2006-12-31 | $193.11K | -96.67% |
| 2005-12-31 | $5.79 Million | +16.68% |
| 2004-12-31 | $4.97 Million | +24.46% |
| 2003-12-31 | $3.99 Million | +294.83% |
| 2002-12-31 | $1.01 Million | -45.92% |
| 2001-12-31 | $1.87 Million | +192.00% |
| 2000-12-31 | $639.91K | -77.31% |
| 1999-12-31 | $2.82 Million | -26.46% |
| 1998-12-31 | $3.83 Million | +140.62% |
| 1997-12-31 | $1.59 Million | +414.11% |
| 1996-12-31 | $309.96K | -- |
About GeoVax Labs Inc
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marb… Read more